STOCK TITAN

[6-K] GSK plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

The Bank of Nova Scotia (NYSE: BNS) has filed a Preliminary Pricing Supplement (Form 424B2) for an upcoming debt offering of Callable Fixed-Rate Notes due July 28, 2033. Key commercial terms are set at issuance price 100% of principal, semi-annual coupons of 5.10% per annum and a final maturity of eight years. The notes are issued under the Bank’s Senior Note Program, Series B and qualify as bail-inable senior unsecured obligations under Canadian law.

  • Size & denomination: Aggregate principal to be determined on trade date (expected July 24 2025); minimum investment US$1,000 and integral multiples thereof.
  • Coupon & accrual: 5.10% fixed, calculated on a 30/360 basis, payable every 28 January and 28 July, starting 28 January 2026.
  • Issuer call feature: The Bank may redeem the notes in whole (not in part) on any interest payment date beginning July 2026, with 10 business-day notice. If called, holders receive par plus accrued interest only up to the call date—creating reinvestment risk.
  • Ranking & security: Senior, unsubordinated, unsecured; pari passu with other senior debt but not insured by CDIC or FDIC. Subject to statutory bail-in conversion under the Canada Deposit Insurance Corporation Act, meaning principal and unpaid interest can be converted into common equity or extinguished if regulators trigger resolution powers.
  • Distribution: Lead underwriter and affiliate Scotia Capital (USA) Inc. will purchase at par and resell to dealers at up to a 2.00% discount. Net proceeds to the Bank estimated at ≥98% of face, before hedging profits.
  • Liquidity: No listing on any securities exchange; secondary market making, if any, will be discretionary. Investors should be prepared to hold to maturity.
  • Risk highlights: Credit risk of BNS, potential bail-in conversion, call/reinvestment risk, price sensitivity to interest-rate moves, limited liquidity and potential conflicts arising from the Calculation Agent role held by an affiliate.

Additional sections outline Canadian and U.S. tax treatments, circumstances for tax-motivated redemption, and prohibitions on retail sales in the EEA and U.K. The document is preliminary; final pricing supplement may modify terms.

La Bank of Nova Scotia (NYSE: BNS) ha depositato un Supplemento Preliminare di Prezzo (Modulo 424B2) per un'imminente emissione di debito consistente in Note a Tasso Fisso Richiamabili con scadenza il 28 luglio 2033. I termini commerciali principali prevedono un prezzo di emissione pari al 100% del capitale, cedole semestrali del 5,10% annuo e una durata finale di otto anni. Le note sono emesse nell’ambito del Senior Note Program, Serie B della banca e sono qualificate come obbligazioni senior non garantite con clausola di bail-in secondo la legge canadese.

  • Dimensione e denominazione: Il capitale complessivo sarà determinato alla data di negoziazione (prevista per il 24 luglio 2025); investimento minimo di 1.000 USD e multipli integrali di tale importo.
  • Cedola e calcolo: Tasso fisso del 5,10%, calcolato su base 30/360, pagabile ogni 28 gennaio e 28 luglio, a partire dal 28 gennaio 2026.
  • Opzione di richiamo dell’emittente: La banca può rimborsare integralmente (non parzialmente) le note in qualsiasi data di pagamento degli interessi a partire da luglio 2026, con un preavviso di 10 giorni lavorativi. In caso di richiamo, i detentori ricevono il valore nominale più gli interessi maturati fino alla data di richiamo, esponendosi al rischio di reinvestimento.
  • Ranking e garanzie: Senior, non subordinato, non garantito; pari rango con altri debiti senior ma non assicurato da CDIC o FDIC. Soggetto a bail-in secondo la legge canadese (Canada Deposit Insurance Corporation Act), il che significa che capitale e interessi non pagati possono essere convertiti in azioni ordinarie o annullati se le autorità regolatorie attivano i poteri di risoluzione.
  • Distribuzione: Lead underwriter e affiliata Scotia Capital (USA) Inc. acquisteranno a pari valore e rivenderanno ai dealer con uno sconto fino al 2,00%. I proventi netti stimati per la banca sono ≥98% del valore nominale, prima dei profitti da copertura.
  • Liquidità: Nessuna quotazione in mercati regolamentati; eventuale mercato secondario sarà gestito a discrezione. Gli investitori devono essere pronti a mantenere fino alla scadenza.
  • Rischi principali: Rischio di credito di BNS, potenziale conversione in bail-in, rischio di richiamo e reinvestimento, sensibilità ai tassi di interesse, liquidità limitata e possibili conflitti derivanti dal ruolo di Calculation Agent svolto da un affiliato.

Sezioni aggiuntive illustrano trattamenti fiscali canadesi e statunitensi, condizioni per il rimborso motivato da ragioni fiscali e divieti di vendita al dettaglio nell’EEA e nel Regno Unito. Il documento è preliminare; il supplemento finale potrebbe modificare i termini.

El Banco de Nova Scotia (NYSE: BNS) ha presentado un Suplemento Preliminar de Precio (Formulario 424B2) para una próxima emisión de deuda de Notas a Tasa Fija Rescindibles con vencimiento el 28 de julio de 2033. Los términos comerciales clave establecen un precio de emisión del 100% del principal, cupones semestrales del 5.10% anual y un vencimiento final a ocho años. Las notas se emiten bajo el Senior Note Program, Serie B del banco y califican como obligaciones senior no garantizadas con cláusula de rescate (bail-in) conforme a la ley canadiense.

  • Tamaño y denominación: Principal agregado a determinar en la fecha de negociación (esperada para el 24 de julio de 2025); inversión mínima de US$1,000 y múltiplos enteros de esta cantidad.
  • Cupón y cálculo: 5.10% fijo, calculado sobre base 30/360, pagadero cada 28 de enero y 28 de julio, comenzando el 28 de enero de 2026.
  • Opción de rescate del emisor: El banco podrá redimir las notas en su totalidad (no parcialmente) en cualquier fecha de pago de intereses a partir de julio de 2026, con un aviso de 10 días hábiles. Si se rescatan, los tenedores recibirán el valor nominal más los intereses devengados hasta la fecha de rescate, lo que genera riesgo de reinversión.
  • Ranking y garantía: Senior, no subordinado, no garantizado; a la par con otras deudas senior pero no asegurado por CDIC o FDIC. Sujeto a conversión por bail-in bajo la Ley de la Corporación de Seguro de Depósitos de Canadá, lo que significa que el principal y los intereses no pagados pueden convertirse en acciones ordinarias o extinguirse si los reguladores activan poderes de resolución.
  • Distribución: El suscriptor principal y afiliado Scotia Capital (USA) Inc. comprará a la par y revenderá a los distribuidores con un descuento de hasta el 2.00%. Los ingresos netos estimados para el banco son ≥98% del valor nominal, antes de ganancias por cobertura.
  • Liquidez: No cotiza en ninguna bolsa de valores; la creación de mercado secundaria, si la hay, será discrecional. Los inversores deben estar preparados para mantener hasta el vencimiento.
  • Aspectos de riesgo: Riesgo crediticio de BNS, potencial conversión por bail-in, riesgo de rescate y reinversión, sensibilidad a movimientos de tasas de interés, liquidez limitada y posibles conflictos derivados del rol de Agente de Cálculo desempeñado por un afiliado.

Secciones adicionales describen tratamientos fiscales en Canadá y EE.UU., circunstancias para redención motivada por impuestos y prohibiciones de venta minorista en el EEE y Reino Unido. El documento es preliminar; el suplemento final puede modificar los términos.

노바스코샤 은행(NYSE: BNS)예비 가격 보충서(Form 424B2)를 제출하여 2033년 7월 28일 만기 콜 가능 고정 금리 채권 발행을 준비 중입니다. 주요 조건은 발행가액이 원금의 100%, 연 5.10%의 반기 쿠폰, 만기는 8년입니다. 해당 채권은 은행의 Senior Note Program, Series B 하에 발행되며, 캐나다 법률상 바일인 가능 선순위 무담보 채무로 분류됩니다.

  • 규모 및 액면가: 총 원금은 거래일(예상 2025년 7월 24일)에 결정되며, 최소 투자금액은 미화 1,000달러 및 그 배수입니다.
  • 쿠폰 및 이자 계산: 5.10% 고정, 30/360 방식으로 계산, 2026년 1월 28일부터 매년 1월 28일과 7월 28일에 지급됩니다.
  • 발행자 콜 옵션: 은행은 2026년 7월부터 모든 이자 지급일에 전액(부분 불가) 상환할 수 있으며, 10영업일 전에 통지해야 합니다. 콜 시 투자자는 액면가와 콜일까지 발생한 이자만 받게 되어 재투자 위험이 발생합니다.
  • 순위 및 담보: 선순위, 무담보, 무보증; 다른 선순위 채무와 동등하지만 CDIC나 FDIC의 보험 대상이 아닙니다. 캐나다 예금보험공사법에 따른 바일인 전환 대상이며, 규제 당국이 해결 권한을 발동할 경우 원금과 미지급 이자가 보통주로 전환되거나 소멸될 수 있습니다.
  • 배포: 주요 인수인 및 계열사인 Scotia Capital (USA) Inc.가 액면가로 매입 후 최대 2.00% 할인된 가격으로 딜러에게 재판매합니다. 은행의 순수익은 헤지 이익 전 기준으로 액면가의 98% 이상으로 추산됩니다.
  • 유동성: 증권거래소 상장은 없으며, 2차 시장 조성은 임의적입니다. 투자자는 만기까지 보유할 준비가 필요합니다.
  • 위험 요약: BNS 신용 위험, 바일인 전환 가능성, 콜 및 재투자 위험, 금리 변동에 따른 가격 민감성, 제한된 유동성, 계열사가 수행하는 계산 대리인 역할에서 발생할 수 있는 이해 상충 위험.

추가 섹션에서는 캐나다 및 미국의 세금 처리, 세금 동기 상환 조건, EEA 및 영국 내 소매 판매 금지 사항을 설명합니다. 문서는 예비 버전이며, 최종 가격 보충서는 조건을 변경할 수 있습니다.

La Banque de Nouvelle-Écosse (NYSE : BNS) a déposé un Supplément Préliminaire de Prix (Formulaire 424B2) pour une prochaine émission de dette portant sur des Notes à taux fixe remboursables anticipativement à échéance le 28 juillet 2033. Les principaux termes commerciaux prévoient un prix d’émission de 100 % du principal, des coupons semestriels de 5,10 % par an et une maturité finale de huit ans. Les notes sont émises dans le cadre du Senior Note Program, Série B de la Banque et sont qualifiées d’obligations senior non garanties avec clause de bail-in selon la législation canadienne.

  • Taille et dénomination : Principal global à déterminer à la date de transaction (prévue au 24 juillet 2025) ; investissement minimum de 1 000 USD et multiples entiers de ce montant.
  • Coupon et calcul : 5,10 % fixe, calculé selon une base 30/360, payable chaque 28 janvier et 28 juillet, à compter du 28 janvier 2026.
  • Option de remboursement anticipé de l’émetteur : La Banque peut racheter les notes intégralement (pas partiellement) à toute date de paiement des intérêts à partir de juillet 2026, avec un préavis de 10 jours ouvrables. En cas de remboursement anticipé, les porteurs recevront la valeur nominale plus les intérêts courus jusqu’à la date de remboursement, ce qui crée un risque de réinvestissement.
  • Rang et sûreté : Senior, non subordonné, non garanti ; au même rang que les autres dettes senior mais non assuré par la CDIC ou la FDIC. Soumis à une conversion en bail-in selon la Loi sur la Société d’assurance-dépôts du Canada, ce qui signifie que le principal et les intérêts impayés peuvent être convertis en actions ordinaires ou annulés si les régulateurs déclenchent les pouvoirs de résolution.
  • Distribution : Le souscripteur principal et affilié Scotia Capital (USA) Inc. achètera à la valeur nominale et revend aux distributeurs avec une décote pouvant aller jusqu’à 2,00 %. Le produit net estimé pour la Banque est d’au moins 98 % de la valeur nominale, avant profits de couverture.
  • Liquidité : Pas de cotation en bourse ; la tenue de marché secondaire, le cas échéant, sera discrétionnaire. Les investisseurs doivent être prêts à conserver jusqu’à l’échéance.
  • Points clés de risque : Risque de crédit de BNS, potentiel de conversion en bail-in, risque de remboursement anticipé et de réinvestissement, sensibilité aux variations des taux d’intérêt, liquidité limitée et conflits potentiels découlant du rôle d’agent de calcul assuré par une entité affiliée.

Des sections supplémentaires détaillent les traitements fiscaux au Canada et aux États-Unis, les conditions de remboursement motivé par la fiscalité, ainsi que les interdictions de vente au détail dans l’EEE et au Royaume-Uni. Le document est préliminaire ; le supplément final pourrait modifier les termes.

Die Bank of Nova Scotia (NYSE: BNS) hat einen Vorläufigen Preiszusatz (Formular 424B2) für eine bevorstehende Schuldverschreibung von kündbaren Festzinsanleihen mit Fälligkeit am 28. Juli 2033 eingereicht. Die wesentlichen kommerziellen Bedingungen sind ein Ausgabepreis von 100% des Nennwerts, halbjährliche Kupons von 5,10% p.a. und eine Endfälligkeit von acht Jahren. Die Anleihen werden im Rahmen des Senior Note Program, Serie B der Bank ausgegeben und gelten nach kanadischem Recht als verzinsliche unbesicherte Seniorverbindlichkeiten mit Bail-in-Klausel.

  • Größe & Nennwert: Gesamtnennbetrag wird am Handelstag (voraussichtlich 24. Juli 2025) festgelegt; Mindestanlage 1.000 USD und ganzzahlige Vielfache davon.
  • Kupon & Berechnung: 5,10% fest, berechnet auf Basis 30/360, zahlbar jeweils am 28. Januar und 28. Juli, beginnend am 28. Januar 2026.
  • Emittenten-Kündigungsrecht: Die Bank kann die Anleihen ganz (nicht teilweise) an jedem Zinszahlungstag ab Juli 2026 mit einer Frist von 10 Geschäftstagen zurückzahlen. Bei Kündigung erhalten die Inhaber den Nennwert plus aufgelaufene Zinsen bis zum Kündigungsdatum – dies birgt ein Reinvestitionsrisiko.
  • Rang & Sicherheit: Senior, unbesichert, nicht nachrangig; pari passu mit anderen Seniorverbindlichkeiten, jedoch nicht durch CDIC oder FDIC versichert. Unterliegt der gesetzlichen Bail-in-Umwandlung gemäß dem Canada Deposit Insurance Corporation Act, was bedeutet, dass Kapital und aufgelaufene, nicht gezahlte Zinsen in Stammaktien umgewandelt oder erloschen werden können, falls die Aufsichtsbehörden Abwicklungsbefugnisse ausüben.
  • Distribution: Hauptzeichner und Tochtergesellschaft Scotia Capital (USA) Inc. kauft zum Nennwert und verkauft mit bis zu 2,00% Rabatt an Händler weiter. Nettoerlöse für die Bank werden auf ≥98% des Nennwerts geschätzt, vor Hedging-Gewinnen.
  • Liquidität: Keine Börsennotierung; Sekundärmarktbildung, falls vorhanden, erfolgt nach Ermessen. Anleger sollten bereit sein, bis zur Fälligkeit zu halten.
  • Risikohinweise: Kreditrisiko von BNS, mögliche Bail-in-Umwandlung, Kündigungs- und Reinvestitionsrisiko, Kursanfälligkeit gegenüber Zinsänderungen, eingeschränkte Liquidität und potenzielle Interessenkonflikte durch die Rolle des Berechnungsagenten, die eine Tochtergesellschaft innehat.

Weitere Abschnitte erläutern die steuerliche Behandlung in Kanada und den USA, Umstände für steuerbedingte Rückzahlungen sowie Verkaufsverbote im EWR und Großbritannien. Das Dokument ist vorläufig; der endgültige Preiszusatz kann Bedingungen ändern.

Positive
  • Attractive coupon: Fixed 5.10% yield provides income stability over an 8-year horizon.
  • Senior unsecured ranking: Pari passu with other senior debt of BNS, offering higher recovery than subordinated tiers.
  • Issuer call notice: 10-day call notice affords investors limited but defined planning window.
Negative
  • Bail-in conversion risk: Principal and interest can be converted to equity or written off under CDIC resolution powers.
  • Issuer-friendly call: Semiannual call starting year 1 exposes holders to reinvestment risk if rates fall.
  • No exchange listing: Expected secondary-market liquidity is low; investors may face price concessions to exit.
  • Credit exposure: Payment relies solely on Bank of Nova Scotia’s ability to perform; notes are not insured by CDIC or FDIC.
  • Up-front underwriting discount: Investors effectively pay up to 2% premium above net proceeds received by the issuer.

Insights

TL;DR – 8-year 5.10% BNS notes offer yield pick-up but carry call, bail-in and liquidity risks.

The pricing supplement reveals an unsecured senior issue that targets U.S. dollar investors seeking higher nominal yield versus comparable investment-grade corporates. A 5.10% coupon is attractive relative to current 8-year U.S. bank paper; however, the semi-annual call starting year-1 tilts economic optionality toward the issuer, capping duration if rates fall. Structurally, these notes are bail-inable; in a resolution event CDIC can forcibly convert holdings into BNS common shares or write them down, materially elevating tail risk versus traditional senior bank debt outside Canada. Lack of exchange listing plus an underwriting spread up to 2% may translate into immediate secondary-market discounts. Overall, the issue is neutral for BNS credit profile—proceeds support general corporate purposes—yet investors must weigh 1) credit strength of a large Canadian bank, 2) reinvestment risk from potential early calls and 3) limited liquidity. For income-oriented accounts comfortable with bank resolution frameworks, the notes can play a supplemental role, but they are not a substitute for insured deposits.

TL;DR – Bail-in conversion language materially subordinates investors to regulatory action.

These securities fall squarely under Canada’s Total Loss-Absorbing Capacity regime. Holders explicitly agree to CDIC powers: conversion to equity or extinguishment without compensation beyond new shares, no court consent, Ontario jurisdiction. While senior pari passu in normal times, they functionally embed quasi-TLAC characteristics in stress. Investors should price a conversion premium over non-bail-in senior peers. The call feature beginning July 2026 could also be constrained by OSFI if redemption harms TLAC ratios. Consequently, market liquidity could diminish during systemic stress, amplifying mark-to-market swings. From a regulatory perspective the filing is routine, so impact = neutral for broader markets, but risk-aware investors must incorporate recovery scenarios into valuation frameworks.

La Bank of Nova Scotia (NYSE: BNS) ha depositato un Supplemento Preliminare di Prezzo (Modulo 424B2) per un'imminente emissione di debito consistente in Note a Tasso Fisso Richiamabili con scadenza il 28 luglio 2033. I termini commerciali principali prevedono un prezzo di emissione pari al 100% del capitale, cedole semestrali del 5,10% annuo e una durata finale di otto anni. Le note sono emesse nell’ambito del Senior Note Program, Serie B della banca e sono qualificate come obbligazioni senior non garantite con clausola di bail-in secondo la legge canadese.

  • Dimensione e denominazione: Il capitale complessivo sarà determinato alla data di negoziazione (prevista per il 24 luglio 2025); investimento minimo di 1.000 USD e multipli integrali di tale importo.
  • Cedola e calcolo: Tasso fisso del 5,10%, calcolato su base 30/360, pagabile ogni 28 gennaio e 28 luglio, a partire dal 28 gennaio 2026.
  • Opzione di richiamo dell’emittente: La banca può rimborsare integralmente (non parzialmente) le note in qualsiasi data di pagamento degli interessi a partire da luglio 2026, con un preavviso di 10 giorni lavorativi. In caso di richiamo, i detentori ricevono il valore nominale più gli interessi maturati fino alla data di richiamo, esponendosi al rischio di reinvestimento.
  • Ranking e garanzie: Senior, non subordinato, non garantito; pari rango con altri debiti senior ma non assicurato da CDIC o FDIC. Soggetto a bail-in secondo la legge canadese (Canada Deposit Insurance Corporation Act), il che significa che capitale e interessi non pagati possono essere convertiti in azioni ordinarie o annullati se le autorità regolatorie attivano i poteri di risoluzione.
  • Distribuzione: Lead underwriter e affiliata Scotia Capital (USA) Inc. acquisteranno a pari valore e rivenderanno ai dealer con uno sconto fino al 2,00%. I proventi netti stimati per la banca sono ≥98% del valore nominale, prima dei profitti da copertura.
  • Liquidità: Nessuna quotazione in mercati regolamentati; eventuale mercato secondario sarà gestito a discrezione. Gli investitori devono essere pronti a mantenere fino alla scadenza.
  • Rischi principali: Rischio di credito di BNS, potenziale conversione in bail-in, rischio di richiamo e reinvestimento, sensibilità ai tassi di interesse, liquidità limitata e possibili conflitti derivanti dal ruolo di Calculation Agent svolto da un affiliato.

Sezioni aggiuntive illustrano trattamenti fiscali canadesi e statunitensi, condizioni per il rimborso motivato da ragioni fiscali e divieti di vendita al dettaglio nell’EEA e nel Regno Unito. Il documento è preliminare; il supplemento finale potrebbe modificare i termini.

El Banco de Nova Scotia (NYSE: BNS) ha presentado un Suplemento Preliminar de Precio (Formulario 424B2) para una próxima emisión de deuda de Notas a Tasa Fija Rescindibles con vencimiento el 28 de julio de 2033. Los términos comerciales clave establecen un precio de emisión del 100% del principal, cupones semestrales del 5.10% anual y un vencimiento final a ocho años. Las notas se emiten bajo el Senior Note Program, Serie B del banco y califican como obligaciones senior no garantizadas con cláusula de rescate (bail-in) conforme a la ley canadiense.

  • Tamaño y denominación: Principal agregado a determinar en la fecha de negociación (esperada para el 24 de julio de 2025); inversión mínima de US$1,000 y múltiplos enteros de esta cantidad.
  • Cupón y cálculo: 5.10% fijo, calculado sobre base 30/360, pagadero cada 28 de enero y 28 de julio, comenzando el 28 de enero de 2026.
  • Opción de rescate del emisor: El banco podrá redimir las notas en su totalidad (no parcialmente) en cualquier fecha de pago de intereses a partir de julio de 2026, con un aviso de 10 días hábiles. Si se rescatan, los tenedores recibirán el valor nominal más los intereses devengados hasta la fecha de rescate, lo que genera riesgo de reinversión.
  • Ranking y garantía: Senior, no subordinado, no garantizado; a la par con otras deudas senior pero no asegurado por CDIC o FDIC. Sujeto a conversión por bail-in bajo la Ley de la Corporación de Seguro de Depósitos de Canadá, lo que significa que el principal y los intereses no pagados pueden convertirse en acciones ordinarias o extinguirse si los reguladores activan poderes de resolución.
  • Distribución: El suscriptor principal y afiliado Scotia Capital (USA) Inc. comprará a la par y revenderá a los distribuidores con un descuento de hasta el 2.00%. Los ingresos netos estimados para el banco son ≥98% del valor nominal, antes de ganancias por cobertura.
  • Liquidez: No cotiza en ninguna bolsa de valores; la creación de mercado secundaria, si la hay, será discrecional. Los inversores deben estar preparados para mantener hasta el vencimiento.
  • Aspectos de riesgo: Riesgo crediticio de BNS, potencial conversión por bail-in, riesgo de rescate y reinversión, sensibilidad a movimientos de tasas de interés, liquidez limitada y posibles conflictos derivados del rol de Agente de Cálculo desempeñado por un afiliado.

Secciones adicionales describen tratamientos fiscales en Canadá y EE.UU., circunstancias para redención motivada por impuestos y prohibiciones de venta minorista en el EEE y Reino Unido. El documento es preliminar; el suplemento final puede modificar los términos.

노바스코샤 은행(NYSE: BNS)예비 가격 보충서(Form 424B2)를 제출하여 2033년 7월 28일 만기 콜 가능 고정 금리 채권 발행을 준비 중입니다. 주요 조건은 발행가액이 원금의 100%, 연 5.10%의 반기 쿠폰, 만기는 8년입니다. 해당 채권은 은행의 Senior Note Program, Series B 하에 발행되며, 캐나다 법률상 바일인 가능 선순위 무담보 채무로 분류됩니다.

  • 규모 및 액면가: 총 원금은 거래일(예상 2025년 7월 24일)에 결정되며, 최소 투자금액은 미화 1,000달러 및 그 배수입니다.
  • 쿠폰 및 이자 계산: 5.10% 고정, 30/360 방식으로 계산, 2026년 1월 28일부터 매년 1월 28일과 7월 28일에 지급됩니다.
  • 발행자 콜 옵션: 은행은 2026년 7월부터 모든 이자 지급일에 전액(부분 불가) 상환할 수 있으며, 10영업일 전에 통지해야 합니다. 콜 시 투자자는 액면가와 콜일까지 발생한 이자만 받게 되어 재투자 위험이 발생합니다.
  • 순위 및 담보: 선순위, 무담보, 무보증; 다른 선순위 채무와 동등하지만 CDIC나 FDIC의 보험 대상이 아닙니다. 캐나다 예금보험공사법에 따른 바일인 전환 대상이며, 규제 당국이 해결 권한을 발동할 경우 원금과 미지급 이자가 보통주로 전환되거나 소멸될 수 있습니다.
  • 배포: 주요 인수인 및 계열사인 Scotia Capital (USA) Inc.가 액면가로 매입 후 최대 2.00% 할인된 가격으로 딜러에게 재판매합니다. 은행의 순수익은 헤지 이익 전 기준으로 액면가의 98% 이상으로 추산됩니다.
  • 유동성: 증권거래소 상장은 없으며, 2차 시장 조성은 임의적입니다. 투자자는 만기까지 보유할 준비가 필요합니다.
  • 위험 요약: BNS 신용 위험, 바일인 전환 가능성, 콜 및 재투자 위험, 금리 변동에 따른 가격 민감성, 제한된 유동성, 계열사가 수행하는 계산 대리인 역할에서 발생할 수 있는 이해 상충 위험.

추가 섹션에서는 캐나다 및 미국의 세금 처리, 세금 동기 상환 조건, EEA 및 영국 내 소매 판매 금지 사항을 설명합니다. 문서는 예비 버전이며, 최종 가격 보충서는 조건을 변경할 수 있습니다.

La Banque de Nouvelle-Écosse (NYSE : BNS) a déposé un Supplément Préliminaire de Prix (Formulaire 424B2) pour une prochaine émission de dette portant sur des Notes à taux fixe remboursables anticipativement à échéance le 28 juillet 2033. Les principaux termes commerciaux prévoient un prix d’émission de 100 % du principal, des coupons semestriels de 5,10 % par an et une maturité finale de huit ans. Les notes sont émises dans le cadre du Senior Note Program, Série B de la Banque et sont qualifiées d’obligations senior non garanties avec clause de bail-in selon la législation canadienne.

  • Taille et dénomination : Principal global à déterminer à la date de transaction (prévue au 24 juillet 2025) ; investissement minimum de 1 000 USD et multiples entiers de ce montant.
  • Coupon et calcul : 5,10 % fixe, calculé selon une base 30/360, payable chaque 28 janvier et 28 juillet, à compter du 28 janvier 2026.
  • Option de remboursement anticipé de l’émetteur : La Banque peut racheter les notes intégralement (pas partiellement) à toute date de paiement des intérêts à partir de juillet 2026, avec un préavis de 10 jours ouvrables. En cas de remboursement anticipé, les porteurs recevront la valeur nominale plus les intérêts courus jusqu’à la date de remboursement, ce qui crée un risque de réinvestissement.
  • Rang et sûreté : Senior, non subordonné, non garanti ; au même rang que les autres dettes senior mais non assuré par la CDIC ou la FDIC. Soumis à une conversion en bail-in selon la Loi sur la Société d’assurance-dépôts du Canada, ce qui signifie que le principal et les intérêts impayés peuvent être convertis en actions ordinaires ou annulés si les régulateurs déclenchent les pouvoirs de résolution.
  • Distribution : Le souscripteur principal et affilié Scotia Capital (USA) Inc. achètera à la valeur nominale et revend aux distributeurs avec une décote pouvant aller jusqu’à 2,00 %. Le produit net estimé pour la Banque est d’au moins 98 % de la valeur nominale, avant profits de couverture.
  • Liquidité : Pas de cotation en bourse ; la tenue de marché secondaire, le cas échéant, sera discrétionnaire. Les investisseurs doivent être prêts à conserver jusqu’à l’échéance.
  • Points clés de risque : Risque de crédit de BNS, potentiel de conversion en bail-in, risque de remboursement anticipé et de réinvestissement, sensibilité aux variations des taux d’intérêt, liquidité limitée et conflits potentiels découlant du rôle d’agent de calcul assuré par une entité affiliée.

Des sections supplémentaires détaillent les traitements fiscaux au Canada et aux États-Unis, les conditions de remboursement motivé par la fiscalité, ainsi que les interdictions de vente au détail dans l’EEE et au Royaume-Uni. Le document est préliminaire ; le supplément final pourrait modifier les termes.

Die Bank of Nova Scotia (NYSE: BNS) hat einen Vorläufigen Preiszusatz (Formular 424B2) für eine bevorstehende Schuldverschreibung von kündbaren Festzinsanleihen mit Fälligkeit am 28. Juli 2033 eingereicht. Die wesentlichen kommerziellen Bedingungen sind ein Ausgabepreis von 100% des Nennwerts, halbjährliche Kupons von 5,10% p.a. und eine Endfälligkeit von acht Jahren. Die Anleihen werden im Rahmen des Senior Note Program, Serie B der Bank ausgegeben und gelten nach kanadischem Recht als verzinsliche unbesicherte Seniorverbindlichkeiten mit Bail-in-Klausel.

  • Größe & Nennwert: Gesamtnennbetrag wird am Handelstag (voraussichtlich 24. Juli 2025) festgelegt; Mindestanlage 1.000 USD und ganzzahlige Vielfache davon.
  • Kupon & Berechnung: 5,10% fest, berechnet auf Basis 30/360, zahlbar jeweils am 28. Januar und 28. Juli, beginnend am 28. Januar 2026.
  • Emittenten-Kündigungsrecht: Die Bank kann die Anleihen ganz (nicht teilweise) an jedem Zinszahlungstag ab Juli 2026 mit einer Frist von 10 Geschäftstagen zurückzahlen. Bei Kündigung erhalten die Inhaber den Nennwert plus aufgelaufene Zinsen bis zum Kündigungsdatum – dies birgt ein Reinvestitionsrisiko.
  • Rang & Sicherheit: Senior, unbesichert, nicht nachrangig; pari passu mit anderen Seniorverbindlichkeiten, jedoch nicht durch CDIC oder FDIC versichert. Unterliegt der gesetzlichen Bail-in-Umwandlung gemäß dem Canada Deposit Insurance Corporation Act, was bedeutet, dass Kapital und aufgelaufene, nicht gezahlte Zinsen in Stammaktien umgewandelt oder erloschen werden können, falls die Aufsichtsbehörden Abwicklungsbefugnisse ausüben.
  • Distribution: Hauptzeichner und Tochtergesellschaft Scotia Capital (USA) Inc. kauft zum Nennwert und verkauft mit bis zu 2,00% Rabatt an Händler weiter. Nettoerlöse für die Bank werden auf ≥98% des Nennwerts geschätzt, vor Hedging-Gewinnen.
  • Liquidität: Keine Börsennotierung; Sekundärmarktbildung, falls vorhanden, erfolgt nach Ermessen. Anleger sollten bereit sein, bis zur Fälligkeit zu halten.
  • Risikohinweise: Kreditrisiko von BNS, mögliche Bail-in-Umwandlung, Kündigungs- und Reinvestitionsrisiko, Kursanfälligkeit gegenüber Zinsänderungen, eingeschränkte Liquidität und potenzielle Interessenkonflikte durch die Rolle des Berechnungsagenten, die eine Tochtergesellschaft innehat.

Weitere Abschnitte erläutern die steuerliche Behandlung in Kanada und den USA, Umstände für steuerbedingte Rückzahlungen sowie Verkaufsverbote im EWR und Großbritannien. Das Dokument ist vorläufig; der endgültige Preiszusatz kann Bedingungen ändern.

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of July 2025
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
 GSK plc (the 'Company')
 
Transaction notification
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Sally Jackson
b)
Position/status
SVP, Global Communications and CEO Office
 
c)
Initial notification/amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
  
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
 
1
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Dylan Jackson
 
b)
Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
 
1
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
  
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Victoria Whyte
 
b)
Position/status
Company Secretary
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
 
139
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
 
e)
Date of the transaction
2025-07-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Iain Whyte
 
b)
Position/status
PCA of Ms V Whyte (Company Secretary)
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor 
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£14.4903
1,290
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
2025-07-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
Emma Walmsley
 
b)
Position/status
Chief Executive Officer
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£14.4903
118.489
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
2025-07-11
 
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Diana Conrad
b)
Position/status
 
Chief People Officer
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
 
1,380.565
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
James Ford
b)
Position/status
 
SVP and Group General Counsel, Legal and Compliance
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
2,315.664
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Sally Jackson
b)
Position/status
 
SVP, Global Communications and CEO Office
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
862.794
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Dylan Jackson
b)
Position/status
 
PCA of Sally Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
156.971
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
David Redfern
b)
Position/status
 
President Corporate Development
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
7,028.653
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Regis Simard
b)
Position/status
 
President, Global Supply Chain
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
 
GSK plc
b)
LEI
 
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
2,929.122
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Philip Thomson
b)
Position/status
 
President, Global Affairs
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
 
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
2,401.114
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
Price
  
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Kate Thomson
b)
Position/status
 
PCA of Philip Thomson (President, Global Affairs)
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
122.458
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
    Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Deborah Waterhouse
b)
Position/status
 
CEO, ViiV Healthcare and President, Global Health, GSK
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
1,432.489
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
    Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Tony Wood
b)
Position/status
 
Chief Scientific Officer
c)
Initial notification/ amendment
 
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
 
Volume(s)
 
 
£14.4903
1,422.165
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
    Price
 
N/A (single transaction)
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction 
 
London Stock Exchange (XLON)
 
 
 
1.
Details of PDMR/person closely associated with them ('PCA')
 
a)
Name
 
Victoria Whyte
b)
Position/status
Company Secretary
 
c)
Initial notification/ amendment
Initial notification
 
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 
a)
Name
GSK plc
 
b)
LEI
5493000HZTVUYLO1D793
 
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 
a)
Description of the financial instrument
Ordinary shares of 31 ¼ pence each ('Ordinary Shares')
 
ISIN: GB00BN7SWP63
 
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
 
c)
Price(s) and volume(s)
 
Price(s)
Volume(s)
 
 
 
£14.4903
1.491
 
 
 
 
 
 
 
d)
Aggregated information
 
Aggregated volume
 
    Price
 
N/A (single transaction)
 
e)
Date of the transaction
 
2025-07-11
f)
Place of the transaction
 
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: July 15, 2025
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc

FAQ

What is the coupon rate on Bank of Nova Scotia’s Callable Notes (BNS)?

The notes pay 5.10% fixed interest, calculated on a 30/360 basis and paid semi-annually.

When can Bank of Nova Scotia call the 2033 notes?

The Bank may redeem the notes in whole on any interest payment date starting July 2026, with 10 business-day prior notice.

Are the BNS Callable Notes insured by CDIC or FDIC?

No. The notes are uninsured senior unsecured obligations and are subject to Canadian bail-in powers.

What is the minimum investment for the BNS 5.10% notes?

The notes are issued in denominations of US$1,000; the minimum initial purchase is US$1,000.

Will the BNS Callable Notes be listed on an exchange?

No exchange or automated quotation system listing is planned, so secondary liquidity may be limited.

How is the issue priced and what are underwriting fees?

Price to public is 100%; dealers receive up to a 2.00% discount, leaving at least 98% of proceeds to the Bank.
GSK PLC

NYSE:GSK

GSK Rankings

GSK Latest News

GSK Latest SEC Filings

GSK Stock Data

78.88B
2.04B
0.06%
17.05%
0.91%
Drug Manufacturers - General
Healthcare
Link
United Kingdom
England